Caricamento...
Interleukin-6 and severe COVID-19: a systematic review and meta-analysis
BACKGROUND: Evidence links COVID-19 severity to hyper-inflammation. Treatment with tocilizumab, a monoclonal antibody directed against the interleukin-6 (IL-6) receptor, was shown to lead to clinical improvement in patients with severe COVID-19. We, therefore, performed the present systematic review...
Salvato in:
| Pubblicato in: | Eur Cytokine Netw |
|---|---|
| Autori principali: | , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Libbey Eurotext
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7530350/ https://ncbi.nlm.nih.gov/pubmed/32933891 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1684/ecn.2020.0448 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|